Clearmind Featured in Bipartisan Veterans Therapy Bill

WASHINGTON D.C. – The recent introduction of bipartisan legislation in the U.S. House of Representatives has drawn attention to Clearmind Medicine Inc.‘s proprietary compound MEAI as part of efforts to broaden veterans’ access to certain emerging therapies.

Clearmind announced that MEAI was explicitly named in H.R. 7091, the Expanding Veterans’ Access to Emerging Treatments Act of 2026. The bill directs the Department of Veterans Affairs to set up programs for investigational research and extended access to innovative treatments addressing unmet needs among veterans, particularly for conditions such as alcohol use disorder and PTSD.

Alongside MEAI, the legislation lists psilocybin, MDMA, 5-MeO-DMT, ibogaine, ketamine, and other compounds that the VA secretary may designate. This represents the first federal legislative mention of MEAI, which Clearmind describes as a non-hallucinogenic neuroplastogen developed to promote brain plasticity without inducing hallucinogenic effects.

The bill remains in its early stages, having been introduced recently in the 119th Congress, with no recorded co-sponsors or committee action detailed in public records as of early February 2026.

Zooming out, the inclusion signals continued congressional interest in exploring alternative approaches to veteran mental health and substance use challenges, building on prior efforts to study psychedelics and related compounds through VA channels. However, passage is uncertain in a divided legislature, and any implementation would depend on funding, regulatory oversight, and clinical evidence.

As the psychedelics and neurotherapeutics sector tracks policy shifts, this development highlights how targeted legislative recognition can spotlight specific compounds, though real-world impact for veterans and companies alike will require further scientific validation and congressional progress.